This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Ocular/ Adnexal Tumors  • Radiation Therapy  • Genetics  • Genetics, Other  • Alert me on articles by topic

The Deborah Iverson, MD, Lectureship

Carol L. Shields, MD; Arupa Ganguly, PhD; Miguel A. Materin, MD; Luiz Teixeira, MD; Arman Mashayekhi, MD; Lori Ann Swanson, BS; Brian P. Marr, MD; Jerry A. Shields, MD

Arch Ophthalmol. 2007;125(8):1017-1024.

Objective  To evaluate the feasibility of genetic testing of uveal melanoma using fine-needle aspiration biopsy (FNAB).

Methods  We reviewed the clinical records of all patients of the Ocular Oncology Service at Wills Eye Hospital with the diagnosis of uveal melanoma who underwent FNAB for genetic testing for chromosome 3 status between November 1, 2005, and March 1, 2006. The FNAB was performed immediately before plaque radiotherapy. The specimens underwent genetic analysis using DNA amplification and microsatellite assay to determine the presence of monosomy 3.

Results  A total of 140 eyes of 140 patients with uveal melanoma were sampled for chromosome 3 abnormalities using FNAB. Monosomy 3 was found in 44 cases (31%), disomy 3 was found in 76 cases (54%), and the genomic DNA yield was insufficient for genetic analysis in 20 cases (14%). Monosomy 3 was found in 16 of 61 small melanomas (26%), 24 of 67 medium melanomas (36%), and 4 of 12 large melanomas (33%). Adequate DNA was achieved in 97% of cases using a 27-gauge needle via the transvitreal tumor apex approach and in 75% of cases using a 30-gauge needle via the transscleral tumor base approach. Factors predictive of monosomy 3 included greater tumor basal dimension (P = .02) and greater distance from the optic disc (P = .02). Transient localized vitreous hemorrhage was found in 46% of eyes. No cases of diffuse vitreous hemorrhage, retinal detachment, or tumor recurrence along the biopsy tract were found.

Conclusion  We found that in most cases, FNAB provides adequate DNA for genetic analysis of uveal melanoma using microsatellite assay.

Author Affiliations: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University (Drs C. L. Shields, Materin, Teixeira, Mashayekhi, Marr, and J. A. Shields), and Department of Genetics, University of Pennsylvania School of Medicine (Dr Ganguly and Ms Swanson), Philadelphia.

RELATED ARTICLE

Molecular Prognostic Testing in Uveal Melanoma: Has It Finally Come of Age?
J. William Harbour
Arch Ophthalmol. 2007;125(8):1122-1123.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Visualization of Circulating Melanoma Cells in Peripheral Blood of Patients with Primary Uveal Melanoma
Ulmer et al.
Clin. Cancer Res. 2008;14:4469-4474.
ABSTRACT | FULL TEXT  

Cytogenetics in the Management of Uveal Melanoma: Are We There Yet?
Robertson
Arch Ophthalmol 2008;126:409-410.
FULL TEXT  

The Future Promise and the Current Reality of Genetic Prognostication in Patients With Uveal Melanoma
Tsai and O'Brien
Arch Ophthalmol 2008;126:413-415.
FULL TEXT  

Role of Cytogenetics in Management of Uveal Melanoma
Shields et al.
Arch Ophthalmol 2008;126:416-419.
FULL TEXT  

Molecular Prognostic Testing in Uveal Melanoma: Has It Finally Come of Age?
Harbour
Arch Ophthalmol 2007;125:1122-1123.
FULL TEXT